From February 17, 2024 to March 31, 2024, the company has repurchased 3,469,900 shares, representing 0.74% for CLP 57.33 million. With this, the company has completed the repurchase of 3,469,900 shares, representing 0.74% for CLP 57.33 million under the buyback announced on February 19, 2024.
Vcanbio Cell & Gene Engineering Corp., Ltd
Equities
600645
CNE000000545
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
20.18 CNY | -7.73% | +13.37% | -0.44% |
1st Jan change | Capi. | |
---|---|---|
-0.44% | 1.29B | |
-1.29% | 12.64B | |
-0.47% | 8.46B | |
+5.68% | 5.66B | |
+22.61% | 5.27B | |
-2.03% | 4.49B | |
-53.56% | 3.11B | |
+19.30% | 2.87B | |
-8.42% | 2.23B | |
-3.55% | 1.89B |
- Stock Market
- Equities
- 600645 Stock
- News Vcanbio Cell & Gene Engineering Corp., Ltd
- Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024.